title: RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion             and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells             in vitro.
abstract: Osteosarcoma is the most common primary malignancy of the bone. There have             been some advances in surgical and chemotherapeutic strategies, but it is still             a tumor with a high mortality rate in children and young adults. Mitogen-activated             protein kinase/extracellular signal regulated kinase (ERK) pathway plays an essential             role in the development and progression of various tumors. ERK1/2 is a key component             of this pathway and hyperactivated in different tumors including osteosarcoma.             This study aimed to investigate whether downregulation of ERK1/2 by siRNA (small             interfering RNA) could inhibit cell proliferation and invasion and increase chemosensitivity             to cisplatin in human osteosarcoma U2-OS cells in vitro. Results showed that the             downregulation of ERK1/2 expression by siRNA in human osteosarcoma cells significantly             inhibited cell proliferation and invasion in vitro. Furthermore, ERK1/2 knockdown             led to cell arrest in the G1/G0 phase of the cell cycle, and eventual apoptosis             and chemosensitivity enhancement in tumor cells. Our data reveal that RNAi-mediated             downregulation of ERK1/2 expression can lead to potent antitumor activity and             chemosensitizing effects in human osteosarcoma.
authors.affiliation: Department of Orthopaedics, Second Affiliated Hospital, Shandong University, 247 Beiyuan Da Street, Jinan 250033, PR China.
authors.forename: Haipeng
authors.initials: H
authors.lastname: Si
authors.forename: Changliang
authors.initials: C
authors.lastname: Peng
authors.forename: Jingjing
authors.initials: J
authors.lastname: Li
authors.forename: Xiqian
authors.initials: X
authors.lastname: Wang
authors.forename: Lianwen
authors.initials: L
authors.lastname: Zhai
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Li
authors.forename: Jianmin
authors.initials: J
authors.lastname: Li
mesh_terms: D000293:Adolescent; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D048708:Cell Growth Processes / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D002648:Child; D002945:Cisplatin / Q000494:pharmacology*; D015536:Down-Regulation; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1 / Q000172:deficiency / Q000235:genetics; D048052:Mitogen-Activated Protein Kinase 3 / Q000172:deficiency / Q000235:genetics; D012516:Osteosarcoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics*; D014162:Transfection
chemical_list: D034741:RNA, Small Interfering; D051057:Proto-Oncogene Proteins c-akt; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D002945:Cisplatin